GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...

The U.S. Centers for Disease Control and Prevention decided, opens new tab to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration ...

Your support makes all the difference. Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

Clover Biopharmaceuticals Ltd. (HK:2197) has released an update. Clover Biopharmaceuticals announced promising results from its Phase I trial of the RSV vaccine candidate SCB-1019, demonstrating ...

Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%. Vaccine sales are expected to decrease at low-single-digit percent.

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...